Residency · Residency · Neurosurgery
Pituitary Adenomas and the Endoscopic Endonasal Approach
Overview
Pituitary adenomas account for approximately 15% of intracranial tumors. They are classified as functional (hormone-secreting) or non-functional based on endocrine activity, and as microadenomas (<10 mm) or macroadenomas (>=10 mm) based on size. The endoscopic endonasal transsphenoidal approach has become the standard surgical technique, offering excellent visualization, high resection rates, and low morbidity. Successful management requires close collaboration between neurosurgery and endocrinology.
Classification
By Size
Microadenomas are under 10 mm, macroadenomas are 10 mm or larger, and giant adenomas reach 40 mm or greater.
By Function
Non-functioning adenomas account for 30-40% of pituitary tumors and present with mass effect. Prolactinomas are the most common functional adenoma at approximately 40%. GH-secreting (somatotroph) adenomas represent about 15% and cause acromegaly or gigantism. ACTH-secreting (corticotroph) adenomas account for 5-10% and cause Cushing disease. TSH-secreting (thyrotroph) adenomas are rare at less than 1% and cause secondary hyperthyroidism. Gonadotroph adenomas often appear clinically non-functioning despite producing FSH/LH subunits.
| Adenoma Type | Frequency | Hormone | Clinical Syndrome | Primary Treatment |
|---|---|---|---|---|
| Non-functioning | 30-40% | None (or FSH/LH subunits) | Mass effect, hypopituitarism | Surgery |
| Prolactinoma | ~40% | Prolactin | Amenorrhea, galactorrhea, infertility | Dopamine agonists (medical) |
| Somatotroph | ~15% | GH | Acromegaly/gigantism | Surgery |
| Corticotroph | 5-10% | ACTH | Cushing disease | Surgery |
| Thyrotroph | <1% | TSH | Secondary hyperthyroidism | Surgery |
Knosp Classification (Cavernous Sinus Invasion)
The Knosp classification grades cavernous sinus involvement based on the relationship of tumor to the intracavernous ICA. Grade 0 indicates no cavernous sinus involvement. Grade 1 means tumor does not extend beyond the medial tangent of the intracavernous ICA. Grade 2 indicates extension between the medial and lateral tangents. Grade 3 shows extension beyond the lateral tangent. Grade 4 represents total encasement of the intracavernous ICA. Grades 3-4 indicate cavernous sinus invasion, making complete resection unlikely.
| Knosp Grade | Tumor Extent Relative to ICA | Cavernous Sinus Invasion | GTR Likelihood |
|---|---|---|---|
| 0 | No CS involvement | No | Very high |
| 1 | Does not pass medial tangent | Unlikely | High |
| 2 | Between medial and lateral tangents | Possible | Moderate |
| 3 | Beyond lateral tangent | Yes | Low |
| 4 | Total ICA encasement | Yes | Very low |
Clinical Presentation
Mass Effect (Non-Functioning Macroadenomas)
Non-functioning macroadenomas present primarily through mass effect. Visual field deficits, classically bitemporal hemianopia from chiasmal compression, may progress to unilateral or bilateral visual loss. Headache results from dural stretching or cavernous sinus invasion. Hypopituitarism develops from compression of normal pituitary tissue, with GH and gonadotropins typically lost first, followed by TSH, then ACTH. Pituitary apoplexy represents acute hemorrhage or infarction within the adenoma, presenting with sudden severe headache, visual loss, ophthalmoplegia, and altered consciousness. It may be life-threatening and requires urgent corticosteroid replacement and possible emergent surgery.
Hormone Hypersecretion Syndromes
Prolactinomas cause amenorrhea, galactorrhea, and infertility in women, and decreased libido, erectile dysfunction, and gynecomastia in men. Men often present with macroadenomas due to delayed diagnosis. Acromegaly manifests with coarsened facial features, enlarged hands and feet, prognathism, carpal tunnel syndrome, sleep apnea, diabetes, cardiomyopathy, and arthropathy. Cushing disease produces central obesity, moon facies, buffalo hump, striae, hypertension, diabetes, osteoporosis, proximal myopathy, and psychiatric disturbances. TSH-secreting adenomas cause hyperthyroidism with elevated or inappropriately normal TSH.
Endocrine Workup
A comprehensive baseline panel includes prolactin, IGF-1, morning cortisol, ACTH, free T4, TSH, LH, FSH, testosterone (males), and estradiol (females). A prolactin level above 200 ng/mL is virtually diagnostic of prolactinoma, whereas the "stalk effect" from compression of the stalk by any mass causes mild elevation (20-100 ng/mL) that can mimic a prolactinoma. Acromegaly is confirmed by elevated IGF-1 and an oral glucose tolerance test showing failure to suppress GH to below 1 ng/mL. The Cushing disease workup involves 24-hour urinary free cortisol, late-night salivary cortisol, 1 mg overnight dexamethasone suppression test, and inferior petrosal sinus sampling with CRH stimulation if biochemical Cushing is confirmed and MRI is equivocal.
<image> Coronal MRI (T1 post-gadolinium) showing a pituitary macroadenoma with suprasellar extension compressing the optic chiasm from below. The normal pituitary gland is displaced superiorly as a thin rim of enhancing tissue. The Knosp classification is illustrated with diagrams showing grades 0-4 based on the relationship of tumor to the intracavernous ICA. Key structures are labeled: optic chiasm, pituitary stalk, cavernous ICA, sphenoid sinus. Radiological teaching illustration. </image>
Medical Management
Prolactinomas
Dopamine agonists (cabergoline, bromocriptine) are first-line therapy for prolactinomas, not surgery. Cabergoline normalizes prolactin in over 90% of patients and reduces tumor size in 80-90%. Surgery is reserved for dopamine agonist intolerance, resistance (failure to normalize prolactin or reduce tumor size by 50% or more), CSF leak from tumor shrinkage, or apoplexy. Giant prolactinomas may require debulking before dopamine agonist therapy due to the risk of CSF leak with rapid tumor shrinkage.
Acromegaly
Somatostatin receptor ligands (octreotide LAR, lanreotide) normalize IGF-1 in approximately 50-60% of patients. Pegvisomant, a GH receptor antagonist, normalizes IGF-1 in 90% but does not shrink the tumor. Cabergoline is modestly effective in about 30% of cases, especially with mild IGF-1 elevations. Medical therapy is used preoperatively to reduce tumor size, for residual or recurrent disease, or when surgery is contraindicated.
Cushing Disease
No primary medical therapy matches the efficacy of surgery. Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) are used preoperatively or for recurrent disease. Pasireotide targets SST5 receptors and normalizes urinary free cortisol in about 25%. Mifepristone, a glucocorticoid receptor antagonist, addresses the metabolic complications.
Surgical Management
Endoscopic Endonasal Transsphenoidal Approach
Technique
The nasal phase involves bilateral nasal access, identification of the sphenoid ostia, and removal of the posterior nasal septum to create a binostril corridor. The sphenoid phase requires a wide sphenoidotomy with identification of key landmarks including the sellar floor, carotid prominences, opticocarotid recesses, planum, and clivus. Sphenoid septations are removed but never avulsed. The sellar phase involves opening the sellar floor with a drill or Kerrison rongeurs and incising the dura in a cruciate fashion. Tumor removal proceeds with systematic extracapsular dissection using ring curettes and suction, removing inferior, lateral, then superior components; descent of the diaphragma sellae confirms adequate resection. Angled endoscopes (30 and 45 degrees) allow visualization of residual tumor in lateral recesses and suprasellar regions. Closure employs a fat graft, fascial graft (fascia lata), the vascularized nasoseptal flap (Hadad-Bassagasteguy flap) for large dural defects, dural sealant, and nasal packing.
Extended Endonasal Approaches
Extended approaches include the transplanum/transtuberculum route for suprasellar extension with chiasmal compression, the transclival approach for retroclival pathology, and the transcribriform approach for anterior skull base tumors. These extended approaches require a nasoseptal flap for reconstruction.
Microsurgical (Microscopic) Transsphenoidal Approach
The traditional approach uses the operating microscope with a sublabial or endonasal incision and nasal speculum. It provides more limited visualization compared with the endoscope, especially in lateral and suprasellar recesses, but remains a widely used and valid technique.
Transcranial Approaches
Transcranial approaches are reserved for tumors with significant lateral or anterosuperior extension not accessible transsphenoidally, using a pterional or subfrontal craniotomy. They are typically employed for giant adenomas with a dumbbell configuration.
<image> Stepwise illustration of the endoscopic endonasal transsphenoidal approach. Panel 1: Endoscopic view of the nasal cavity identifying the sphenoid ostium and posterior nasal septum. Panel 2: Sphenoid sinus after wide sphenoidotomy showing the sellar floor, carotid prominences, and opticocarotid recesses. Panel 3: Dural opening with cruciate incision and tumor exposure. Panel 4: Tumor removal with ring curette showing descent of the diaphragma sellae. Panel 5: Reconstruction with fat graft, fascia lata, and nasoseptal flap. Clean surgical illustration with labeled landmarks at each step. </image>
Complications
Postoperative Endocrine Disorders
Diabetes insipidus (DI) is the most common transient complication, occurring in 10-20% of cases, with permanent DI in 1-5%. It results from manipulation of the posterior pituitary or stalk. The classic triphasic response involves DI on days 1-3, followed by SIADH on days 4-7, and then either permanent DI or recovery. Management requires monitoring urine output, specific gravity, and serum sodium, with treatment using desmopressin (DDAVP). SIADH may occur in isolation or as part of the triphasic response, with hyponatremia peaking at days 5-10 postoperatively. New anterior pituitary deficiency occurs in 2-5% after microadenoma surgery and is higher in macroadenomas. The risk of adrenal crisis from acute cortisol deficiency necessitates empiric stress-dose hydrocortisone perioperatively, particularly in Cushing disease where the contralateral adrenal is suppressed.
CSF Leak
CSF leak is the most feared non-endocrine complication, occurring in 2-5% of cases. It presents as clear rhinorrhea, positive beta-2 transferrin, or ring sign on the pillow. The nasoseptal flap (Hadad-Bassagasteguy) has dramatically reduced CSF leak rates in extended approaches. Management includes bed rest, lumbar drain, and return to the operating room for repair if persistent.
Other Complications
Epistaxis, usually from the sphenopalatine artery, is managed with nasal packing or cauterization. ICA injury is rare (under 1%) but catastrophic, managed with direct packing, muscle patch, or emergent endovascular balloon occlusion. Visual worsening from chiasm manipulation, hematoma, or devascularization mandates postoperative visual field testing. Meningitis occurs in less than 1% with antibiotic prophylaxis.
Remission Criteria and Follow-Up
Prolactinoma
Normal prolactin postoperatively indicates remission; the recurrence rate is 10-20% after surgery.
Acromegaly
Biochemical remission is defined as normal age- and sex-adjusted IGF-1 combined with a random GH under 1 ng/mL or nadir GH under 0.4 ng/mL on oral glucose tolerance test. Remission rates are approximately 80-90% for microadenomas and 40-60% for macroadenomas.
Cushing Disease
A morning cortisol below 2 mcg/dL on postoperative days 1-3 (off glucocorticoids) indicates remission. Patients require cortisol replacement for months until the HPA axis recovers. Remission rates are approximately 80-90% for microadenomas and 50-70% for macroadenomas. Recurrence occurs in 10-25% within 10 years, requiring lifelong surveillance.
Clinical Pearls
Prolactin must always be checked before operating on a pituitary mass, since a prolactinoma is treated medically first and operating on an unsuspected prolactinoma can result in CSF leak and unnecessary morbidity. The stalk effect causes mild prolactin elevation (20-100 ng/mL) from any mass compressing the stalk; this should not be confused with a prolactinoma, which typically causes levels exceeding 200 ng/mL for macroadenomas. Pituitary apoplexy is a neurosurgical emergency requiring immediate corticosteroid replacement, with surgery indicated for progressive visual loss or depressed consciousness. Postoperative hyponatremia from SIADH typically peaks at days 5-10, so patients should be counseled before discharge to watch for symptoms, and sodium should be checked at day 7. The nasoseptal flap must be harvested at the start of the case if an extended approach is anticipated, since delayed harvest after mucosal stripping is not possible. Cushing disease patients are profoundly immunosuppressed and require careful perioperative steroid management; adrenal insufficiency after successful adenomectomy requires months of glucocorticoid taper.
<image> Diagram of the triphasic response of diabetes insipidus after transsphenoidal pituitary surgery showing the timeline: Phase 1 (days 1-3) with polyuria and hypernatremia, Phase 2 (days 4-7) with oliguria and hyponatremia (SIADH), and Phase 3 (after day 7) with either recovery or permanent DI. Serum sodium and urine output curves are plotted. Management strategies at each phase are annotated including fluid management and DDAVP use. Clean clinical teaching diagram. </image>
References
- Molitch ME. "Diagnosis and Treatment of Pituitary Adenomas: A Review." JAMA. 2017;317(5):516-524.
- Mehta GU, Lonser RR. "Management of Hormone-Secreting Pituitary Adenomas." Neuro-Oncology. 2017;19(6):762-773.
- Kassam AB, et al. "Endoscopic Endonasal Skull Base Surgery: Analysis of Complications in the Authors' Initial 800 Patients." J Neurosurg. 2011;114(6):1544-1568.
- Knosp E, et al. "Pituitary Adenomas with Invasion of the Cavernous Sinus Space." Neurosurgery. 1993;33(4):610-618.
- Hadad G, et al. "A Novel Reconstructive Technique after Endoscopic Expanded Endonasal Approaches: Vascular Pedicle Nasoseptal Flap." Laryngoscope. 2006;116(10):1882-1886.
